Investigational drug · Phase 2
hMPV vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization, Healthy Volunteers.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
22
Any phase or sponsor naming "hMPV vaccine"
First trial start
2024
Nov 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "hMPV vaccine", any sponsor or status.
- Phase 119
Conditions studied
As listed on its trial records.
- Human Metapneumovirus Immunization
- Respiratory Syncytial Virus Immunization
- Healthy Volunteers
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "hMPV vaccine" as an intervention, largest first.
- Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07810010 · 8,000 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 3, 2028
Drug: Bivalent RSV+HMPV protein vaccine; Placebo · For: Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers
Sites: Bruse, Australia; Blacktown, Australia; Maroubra, Australia · 21 sites in all
- Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07734649 · 2,400 participants (planned) · Start Jul 22, 2026 · Primary completion May 3, 2028
Drug: RSV+HMPV vaccine; Control Vaccine 3 and 3 more · For: Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers
Sites: Gadsden, Alabama; Vestavia Hills, Alabama; Huntington Beach, California · 50 sites in all
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderPivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06686654 · 1,530 participants · Start Nov 11, 2024 · Primary completion Jan 18, 2027
Drug: Investigational hMPV/RSV vaccine; Investigational hMPV vaccine (monovalent) and 4 more · For: Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization
Sites: Phoenix, Arizona; Garden Grove, California; Gardena, California · 24 sites in all
- A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older AdultsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07628049 · 1,456 participants (planned) · Start Jun 5, 2026 · Primary completion Apr 5, 2029
Drug: RSV/hMPV_V low dose vaccine; RSV/hMPV_V medium dose vaccine and 14 more · For: Respiratory Syncytial Virus Infections+Metapneumovirus
Sites: Stockbridge, Georgia; Lenexa, Kansas; Seattle, Washington · 5 sites in all
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidatePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06134648 · 646 participants · Start Nov 1, 2023 · Primary completion Feb 27, 2026
Drug: RSV/hMPV vaccine candidate Dose L; RSV/hMPV vaccine candidate Dose A and 2 more · For: Respiratory Syncytial Virus Infection; Healthy Volunteers; Human Metapneumovirus
Sites: Los Alamitos, California; Los Angeles, California; Rolling Hills Estates, California · 13 sites in all
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
- Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06237296 · 558 participants · Start Jan 23, 2024 · Primary completion Feb 11, 2025
Drug: RSV/hMPV mRNA LNP 1; RSV/hMPV mRNA LNP 2 and 2 more · For: Respiratory Syncytial Virus Infection; Healthy Volunteers; Metapneumovirus Infection
Sites: Gardena, California; Hallandale, Florida; Meridian, Idaho · 17 sites in all
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06604767 · 390 participants · Start Sep 17, 2024 · Primary completion Mar 24, 2026
Drug: parainfluenza virus type 3 vaccine (PIV3); RSV/hMPV/PIV3 vaccine and 3 more · For: Respiratory Syncytial Virus Infection; Metapneumovirus Infection; Parainfluenzae Virus Infection
Sites: Blacktown, Australia; Botany, Australia; Brookvale, Australia · 8 sites in all
- Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 YearsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06583031 · 385 participants · Start Oct 9, 2024 · Primary completion Oct 9, 2025
Drug: RSV/hMPV vaccine dose A1; RSV/hMPV vaccine dose A2 and 11 more · For: RSV Infection; hMPV
Sites: Botany, Australia; Brookvale, Australia; Miranda, Australia · 6 sites in all
- A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07764237 · 375 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 20, 2027
Drug: mRNA-1365 (Profile 2); mRNA-1345 (Profile 1) and 1 more · For: Respiratory Syncytial Virus (RSV); Human Metapneuomovirus (hMPV)
Sites: Québec, Canada; Victoriaville, Canada; Manchester, United Kingdom · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Human metapneumovirus-associated ARI hospitalisation rates in comparison to respiratory syncytial virus and influenza in eastern China, 2020-2024: a time-series analysis.
Lu M, Qiao M, Chen S, et al. · Int J Infect Dis 2026
- Human metapneumovirus: an underestimated cause of severe respiratory infection.
Cilloniz C, Ho A, Rhee C · Ann Am Thorac Soc 2026
- Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.
Lamichhane P, Yang L, Santos C, et al. · J Virol 2026
- Genotype turnover and global evolutionary dynamics of G gene duplication variants in human metapneumovirus: insights from prospective surveillance in Nantong, China, 2024-2025.
Ji X, Liu Z, Cai X, et al. · Front Microbiol 2026
- Stabilization of prefusion hMPV F improves manufacturability and protective immunity across hMPV lineages.
Qu C, Zou J, Niu D, et al. · Virol Sin 2026
- Human Metapneumovirus G Protein Immunogenicity and Safety Explored via Carrier Protein Fusion.
Ren T, Ma K, Lai X, et al. · Trop Med Infect Dis 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.